Counts and Characteristics of Individuals with Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitor Use: A Descriptive Analysis

    Basic Details
    Date Posted
    Friday, July 15, 2022
    Medical Product
    sodium-glucose co-transporter-2 (SGLT-2) inhibitor

    In this report, we examined counts of individuals with sodium-glucose co-transporter-2 (SGLT-2) inhibitor and sitagliptin dispensings in the Sentinel Distributed Database (SDD) along with baseline conditions and other medication use. The study period includes data from March 1, 2013 to June 30, 2018. We distributed this request to six Sentinel Data Partners on September 21, 2021.

    Additional Details
    FDA Center
    Time Period
    March 1, 2013 - June 30, 2018
    Study Type
    Modular Program
    Assessment Type
    Exploratory Analyses
    Population / Cohort
    Individuals aged 20 and older
    Data Sources
    Sentinel Distributed Database (SDD)